Children’s Hospital Los Angeles Names James F. Amatruda, M.D., Ph.D., as Director of the Cancer and Blood Disease Institute
2024年8月13日 - 7:01PM
ビジネスワイヤ(英語)
Children’s Hospital Los Angeles has named James F. Amatruda,
M.D., Ph.D., a highly respected medical leader, clinician, and
researcher with global recognitions, as Director of the Cancer and
Blood Disease Institute (CBDI) and Chief of the Division of
Hematology-Oncology at Children’s Hospital Los Angeles (CHLA). He
had been serving in these roles on an interim basis since September
2023. He is also the new Alfred E. Mann Family Foundation Chair in
Cancer Research.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240813271280/en/
James F. Amatruda, M.D., Ph.D., Director
of the Cancer and Blood Disease Institutes and Alfred E. Mann
Family Foundation Chair in Cancer Research at Children’s Hospital
Los Angeles. (Photo: Business Wire)
“We are thrilled to welcome Dr. Amatruda as the new Director of
the Cancer and Blood Disease Institute and Chief of the Division of
Hematology-Oncology at CHLA,” says Dr. Alan S. Wayne,
Pediatrician-in-Chief and Senior Vice President of Academic Affairs
at CHLA and Pasadena Guild Chair. Dr. Wayne is also Chair of the
Department of Pediatrics at the Keck School of Medicine of USC.
“Dr. Amatruda’s research and clinical work have established him as
an internationally renowned expert in the field of pediatric
cancer. Dr. Amatruda’s leadership will further cement CHLA’s
standing as one of the leading pediatric cancer and blood disease
programs in the nation, and advance research in the development of
safer and more effective therapies for children with cancer.”
As CBDI Director and Division Chief, Dr. Amatruda is leading the
clinical care, research and education programs in pediatric
hematology, oncology, and hematopoietic stem cell
transplantation/cellular therapy at CHLA and USC. He will work with
institutional leadership in strategic planning, recruitment and
program development for the largest pediatric cancer and blood
disease program in the Western U.S. In 2023, U.S. News & World
Report’s Best Children’s Hospitals survey ranked the CBDI No. 3 in
the nation and No. 1 in California and the Pacific region. The CBDI
also functions as the pediatric component of the National Cancer
Institute-designated USC-Norris Comprehensive Cancer Center.
Dr. Amatruda joined CHLA in 2019 as the Director of Basic and
Translational Research overseeing laboratory research within the
CBDI and as a tenured Professor of Pediatrics and Medicine at Keck
School of Medicine of USC. He markedly expanded zebrafish-based
disease research at CHLA, promoting innovative, cross-disciplinary
team science, including fostering bench-to-bedside translational
research in oncology.
Dr. Amatruda’s global recognition as an expert in these areas is
further demonstrated by his leadership in several scientific
organizations. He has held multiple positions in the Children’s
Oncology Group (COG), the national cooperative that oversees all
U.S. clinical trials in pediatric oncology, including Chair of the
Rare Tumors Biology Committee, Chair of the Germ Cell Tumor Biology
Committee, and member of the COG Ewing Sarcoma Biology Committee.
In 2014, he co-founded the international Zebrafish Disease Models
Society and served as its first president. Dr. Amatruda was the
initiating Chair of the Biology Committee for the Malignant Germ
Cell International Collaboration, and currently serves on the
scientific advisory boards of Curing Kids Cancer as well as the Sam
Day, Pablove and William Guy Forbeck Foundations. He is also
co-Chair of the Steering Committee for the National Cancer
Institute’s FusOnC2 Fusion Oncogene Consortium.
Dr. Amatruda received his bachelor’s in Biochemical Sciences
from Harvard University and his M.D.-Ph.D. from Washington
University School of Medicine. He completed his internship and
residency at Brigham and Women’s Hospital in Boston, followed by a
medical oncology fellowship at Dana-Farber/Partners Cancer Care in
Boston. He was a postdoctoral fellow in the laboratory of Dr.
Leonard Zon at Boston Children’s Hospital, then served on the
faculty of UT Southwestern Medical Center in Dallas before coming
to CHLA. He is certified by the American Board of Internal Medicine
with a specialty certification in Medical Oncology.
About Children’s Hospital Los Angeles
Founded in 1901, Children’s Hospital Los Angeles is at the
forefront of pediatric medicine and is the largest provider of
hospital care for children in California. Children’s Hospital is
home to renowned experts who work together across disciplines to
deliver inclusive and compassionate care, and drive advances that
set pediatric standards across the nation and around the globe.
Children’s Hospital Los Angeles provides a level of care to its
diverse population of children that is among the best in the world.
The hospital is consistently ranked in the top 10 in the nation on
U.S. News & World Report’s Honor Roll of Best Children’s
Hospitals, including No. 1 in California and No. 1 in the Pacific
U.S. region. Children’s Hospital Los Angeles embraces its mission
to create hope and build healthier futures. Children’s Hospital Los
Angeles is among the top 10 children’s hospitals for National
Institutes of Health funding. The Saban Research Institute of
Children's Hospital Los Angeles supports the full continuum of
research, allowing physicians and scientists to translate
discoveries into treatments and bring answers to families faster.
The pediatric academic medical center also is home to one of the
largest training programs for pediatricians in the United States.
And the hospital’s commitment to building strong communities is
evident in CHLA’s efforts to fight food insecurity, enhance health
education and literacy, and introduce more people to careers in
health care. To learn more, follow CHLA on Facebook,
Instagram, LinkedIn, YouTube and X,
formerly known as Twitter, and visit CHLA.org/blog.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240813271280/en/
Marlen Bugarin mbugarin@chla.usc.edu